PULM - ポルメイトリックス (Pulmatrix Inc.)

PULMのニュース

   Pulmatrix Earnings, Revenue Beat in Q3 By Investing.com  2022/11/10 16:14:00 Investing.com
Pulmatrix Earnings, Revenue Beat in Q3
   Pulmatrix GAAP EPS of -$1.45 beats by $0.06, revenue of $1.87M beats by $0.71M  2022/11/10 14:12:29 Seeking Alpha
Pulmatrix press release (PULM): Q3 GAAP EPS of -$1.45 beats by $0.06.Revenue of $1.87M (+74.8% Y/Y) beats by $0.71M.
   Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update  2022/11/10 14:05:00 Benzinga
PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash and cash equivalents at end of Q3 2022 LEXINGTON, Mass. , Nov. 10, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM ), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced third quarter financial results for 2022 and provided a corporate update related to its development programs. Ted Raad , Chief Executive Officer of Pulmatrix commented, "In this quarter we have advanced both PUR3100 and PUR1900 towards important data catalysts. We completed patient dosing for PUR3100, our orally inhaled dihydroergotamine (DHE) being developed for the treatment of acute migraine, in a Phase 1 study with data expected to be released in early Q1 2023. In addition to safety and tolerability, the study will evaluate the pharmacokinetics of PUR3100 compared to intravenous DHE.
   Aspergillosis Market is Projected to Boost at a Moderate Growth Rate by (2022-2032) - Evaluated by DelveInsight | Key Companies - F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide, Sanofi  2022/10/10 10:21:35 OpenPR
The Aspergillosis market is expected to surge due to the disease''s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Aspergillosis pipeline products will significantly revolutionize the Aspergillosis market dynamics. DelveInsight''s "Aspergillosis Market Insights, Epidemiology, and
   Here’s the Things Nobody Tells You About: VEON Ltd. (NASDAQ:VEON 2.88%), Pulmatrix, Inc. (NASDAQ:PULM 2.54%)  2022/09/16 00:07:59 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Here’s the Things Nobody Tells You About: VEON Ltd. (NASDAQ:VEON 2.88%), Pulmatrix, Inc. (NASDAQ:PULM 2.54%) appeared first on Stocks Equity .
   Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100  2022/07/12 13:35:58 Seeking Alpha
Pulmatrix (PULM) on Tuesday said it had dosed the first five subjects in its phase 1 trial evaluating its acute migraine treatment PUR3100.The early-stage trial has been designed to…
   Pulmatrix GAAP EPS of -$1.51 misses by $0.10, revenue of $1.16M beats by $0.09M  2022/05/12 13:17:15 Seeking Alpha
Pulmatrix press release (PULM): Q1 GAAP EPS of -$1.51 misses by $0.10.Revenue of $1.16M (-16.5% Y/Y) beats by $0.09M.
   Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update  2022/05/12 13:05:00 PR Newswire
Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass., May 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and…
   Pulmatrix GAAP EPS of -$8.63 misses by $0.83, revenue of $5.17M  2022/03/29 13:15:07 Seeking Alpha
Pulmatrix press release (PULM): FY GAAP EPS of -$8.63 misses by $0.83.Revenue of $5.17M (-59.1% Y/Y).
   Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update  2022/03/29 13:05:00 PR Newswire
LEXINGTON, Mass., March 29, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced fourth quarter…
   Spellbinding stocks: RLX Technology Inc. (NYSE:RLX 3.22%), Pulmatrix, Inc. (NASDAQ:PULM -1.33%)  2021/09/03 23:44:41 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Spellbinding stocks: RLX Technology Inc. (NYSE:RLX 3.22%), Pulmatrix, Inc. (NASDAQ:PULM -1.33%) appeared first on Stocks Equity .
   Highly Traded Technology Stock: NVIDIA Corporation (NASDAQ:NVDA), Pulmatrix, Inc. (NASDAQ:PULM)  2021/08/17 21:09:00 Stock Equity
NVIDIA Corporation (NASDAQ:NVDA) with the stream of -2.49% also noticed, India Pulmatrix, Inc. (NASDAQ:PULM) encountered a rapid change of 1.65% in the last hour of Tuesdays trading session. NVIDIA Corporation The post Highly Traded Technology Stock: NVIDIA Corporation (NASDAQ:NVDA), Pulmatrix, Inc. (NASDAQ:PULM) appeared first on Stocks Equity .
   Is it time to Buy before this weeks earning report Pulmatrix (NASDAQ:PULM)  2021/08/13 04:04:00 Stock Market Daily
Earnings results for Pulmatrix , Analyst Opinion on Pulmatrix , Earnings and Valuation of (NASDAQ:PULM), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Is it time to Buy before this weeks earning report Pulmatrix (NASDAQ:PULM) appeared first on .
   Pulmatrix EPS beats by $0.02, beats on revenue  2021/08/10 13:14:22 Seeking Alpha
   Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update  2021/08/10 13:10:00 Finanzen CH
LEXINGTON, Mass., Aug. 10, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE technology,

calendar